In a presurgical window trial of 132 postmenopausal women with ER-positive, HER2-negative early breast cancer, camizestrant at all doses cut tumour ER expression by about 65%; Ki67 fell more after 12–15 than 5–7 days. The 75 mg dose was well tolerated.
RCTn = 132 women
Robertson et al. Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study